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Abstract
It has been recognized that the HCV (hepatitis C virus) core protein plays an important role in hepatocarcinogenesis. The
functional inactivation of the Rb pathway appears to be a major event for multi-step cancer carcinogenesis. To elucidate the
role of the HCV core protein in hepatocarcinogenesis, we investigated the effect of the HCV core protein on the Rb pathway
in both Rat-1 cell lines, stably expressing the HCV core protein and the doxycycline-regulated cell lines. The HCV core stable
transfectants showed a dramatic decrease in the pRb levels and E2F-1 up-regulation. In the doxycycline-regulated cell lines,
the pRb levels were significantly decreased which are followed by E2F-1 up-regulation. HCV core stable transfectants
showed higher cell growth rates and were sensitize to apoptosis. Thus, our results first indicate that the HCV core protein
decreases the expression of pRb, thereby allowing E2F-1 to be constitutively active, which is thought to result in rapid cell
proliferation or sensitizing to apoptosis. ß 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction
Hepatitis C virus (HCV) is an important causative
agent of the acute and chronic hepatitis, which often
leads to liver cirrhosis and hepatocellular carcinoma
[1]. HCV infection is now recognized to be a major
risk factor for hepatocellular carcinoma. However,
the precise role of HCV in hepatocarcinogenesis re-
mains unknown.
Many researchers have reported that the core pro-
tein of HCV transforms ¢broblasts with or without
the cooperation of the ras oncogene [2,3], trans-sup-
presses some cellular promoters [4^6], and modi¢es
the susceptibility of cultured cells to apoptotic signals
[7^9]. Although the mechanisms of these regulations
are still unclear, it is possible that these properties of
the HCV core protein in£uence host cell growth,
survival, and carcinogenesis. Recently, it was also
reported that transgenic mice expressing the HCV
core gene developed hepatocellular carcinoma [10].
We previously reported that the Rat-1 cell line, sta-
bly expressing HCV core protein, exhibited focus
formation, anchorage-independent growth, and tu-
mor formation in nude mice [3]. Furthermore, de-
pending on the expression level of the core protein,
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the HCV core protein is able to induce the transfor-
mation of Rat-1 cells at various e⁄ciencies.
Recent data have suggested that deregulation of
the restriction point control in the cell cycle G1
phase appears to be required for malignant transfor-
mation [11,12]. The pRb (retinoblastoma tumor sup-
pressor protein) pathway has been regarded as a
functional unit controlling the G1 phase and as an
obligatory oncogenic target [13,14]. In addition, pRb
is important for suppressing growth, facilitating dif-
ferentiation, and inhibiting apoptosis [15]. Therefore,
the Rb pathway perturbation is directly involved in
malignant transformation processes.
To understand the role of the HCV core protein in
hepatocarcinogenesis, it is necessary to investigate
whether the HCV core protein can modulate the
Rb pathway during the transformation processes.
In this study, we investigated the e¡ect of the HCV
core protein on the Rb pathway in both Rat-1 cell
lines, stably expressing the HCV core protein, and
doxycycline-regulated cell lines. In this present study,
we reported that the HCV core protein decreases the
expression of pRb through the down-regulation of
Rb mRNA, thereby allowing E2F-1 to be constitu-
tively active, which is thought to result in rapid cell
proliferation or sensitizing to apoptosis.
2. Materials and methods
2.1. Plasmids and cells
As previously described [3], pCI-neo-core K was
constructed by inserting the PCR-ampli¢ed core re-
gion (amino acids 1^191) of the HCV-K isolate [16]
into the expression vector, pCI-neo (Promega, USA).
The PCR-ampli¢ed core sequences were also inserted
into the expression plasmid, pUHD 10-3, and desig-
nated as pUHD core. The pUHD 10-3 plasmid,
kindly provided by Dr H. Bujard of the University
of California, Berkeley, carries the regulatory region
with human cytomegalovirus (hCMV) minimal pro-
moter and heptamerized upstream tet operator, as
previously described [17,18].
Rat-1 cells, immortalized Rat embryo ¢broblasts,
were maintained in Dulbecco’s modi¢ed Eagle’s me-
dium (DMEM; Gibco BRL, Germany) supplied with
10% fetal bovine serum and transfected with pCI-neo
or pCI-neo-core K using the calcium phosphate co-
precipitation method and selected by G418 treatment
for 2 weeks. Resistant clones were separately propa-
gated and the expression of core gene was analyzed
by western blot. pUHD core was cotransfected with
a pUHD 172-neo in 5:1 ratio into Rat-1 cells to
generate a core-inducible cell line. pUHD 172-neo
provided by Dr H. Bujard encodes a neomycin phos-
photransferase gene and carries the doxycycline
(dox) regulatory region along with the hCMV pro-
moter/enhancer elements and the rtTA-gene [17]. To
select clones that express core under the control of
dox, G418-resistant clones were incubated with me-
dium containing with or without dox (Sigma, USA).
After incubation for 48 h, the cells were harvested
and used for Western blot.
2.2. Reverse transcription^polymerase chain reaction
(RT^PCR)
Total RNA was isolated by the guanidinium/cesi-
um chloride centrifugation method [19] and quanti-
tated by spectrophotometry. One microgram of total
RNA was reverse transcribed using M-MLV Reverse
Transcriptase (Promega). The PCR reaction was car-
ried out under the conditions recommended by the
manufacturer’s instructions (Perkin Elmer Cetus,
USA). Brie£y, 50 Wl of a reaction mixture including
2.5 units of Taq polymerase (Takara, Japan), 5 Wl of
10U bu¡er, 1.5 mM MgCl2, 200 WM dNTPs, 1 Wl of
¢rst-strand cDNA, and 25 pmol each of primer, was
subjected to 28 PCR cycles (denaturation at 94‡C for
1.5 min, annealing at 58‡C for 1 min, and poly-
merization at 72‡C for 1 min). The following primer
pairs were used for PCR ampli¢cation: (1) GAPDH
(sense: 5P-ATCACTGCCACTCAGAAGAC-3P, an-
tisense: 5P-CTTGCTCTCAGTATCCTTGC-3P) ; (2)
Rb (sense: 5P-GTACCGTCTAGCATATCTCC-3P,
antisense: 5P-CTCTGTCACTG-TTACACACC-3P).
2.3. Western blot analysis
Cells were lysed in lysis bu¡er (10 mM Tris (pH
7.4), 5 mM EDTA, 130 mM NaCl, 1% Triton X-100,
PMSF (10 Wg/ml), aprotinin (10 Wg/ml), leupeptin
(10 Wg/ml), 5 mM phenanthroline, and 28 mM benz-
amidine^HCl) for 30 min on ice. The lysates were
cleared by centrifugation at 12 000 rpm for 30 min.
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Lysates were quantitated using the Bradford assay
(Bio-Rad, USA) with bovine serum albumin as a
reference standard. For the Western blotting experi-
ments, each gel slot was loaded with 100 Wg of cell
lysates protein. Electrophoresis was performed in
6.5% or 12% SDS^PAGE (sodium dodecyl sulfate^
polyacrylamide gels) and transferred to PVDF (poly-
vinylidene di£uoride membrane, Millipore, USA).
After incubation with primary antibodies, proteins
were visualized by incubation with horseradish per-
oxidase-conjugated secondary antibodies (Amer-
sham, USA), followed by ECL according to the
manufacturer’s instructions (Amersham). Primary
antibodies against Rb (G3-245; PharMingen,
USA), E2F-1 (KH95; Santa Cruz, USA), and L-actin
(I-19; Santa Cruz) were applied at optimized concen-
trations. HCV core proteins were detected with using
anti-core positive patient’s sera and horseradish per-
oxidase-conjugated anti-human immunoglobulin G
as the primary and secondary antibodies, respec-
tively.
2.4. Determination of pRb half-life
Pulse-chase analysis was performed as described
previously [20]. Brie£y, cells were prestarved for
30 min in methionine-free DMEM media (Gibco
BRL, Germany) and then pulse-labeled for 15 min
with 250 WCi of [35S]methionine (Amersham) fol-
lowed by chase for the indicated time periods. At
each time point, cells were washed with cold PBS
and lysed in EBC lysis bu¡er (150 mM NaCl,
50 mM Tris (pH 8.0), 0.5% NP-40, 100 mM NaF,
200 uM sodium orthovanadate). Lysates were pre-
cleared, and equal concentration of lysates were im-
munoprecipitated with anti-Rb antibody and re-
solved by 6.5% SDS^PAGE. The signals were
detected by autoradiography.
2.5. ac-DEVD-pNA enzymatic cleavage activity
Cells were lysed in lysis bu¡er (50 mM Tris (pH
7.5), 0.03% NP-40, 1.0 mM DTT) for 30 min on ice.
After centrifugation at 12 000 rpm for 30 min at 4‡C,
the supernatant was quantitated using the Bradford
assay (Bio-Rad) with bovine serum albumin as a
reference standard. Lysates (20 Wg) were incubated
with 0.2 mM ac-DEVD-pNA (Enzyme System Prod-
uct, USA) in a total volume of 0.1 ml. Assays were
performed in duplicate, and the results are presented
as the average increase in absorbance at 405 nm.
3. Results
3.1. Establishment of HCV core stable transfectants
and doxycycline-regulated cell lines
The expression of the HCV core protein in the
stable transfectants (cell clones; cores 1, 5, and 6)
and doxycycline-regulated cell lines was examined
by Western blotting analysis (Fig. 1). The HCV
core protein was expressed in three di¡erent stable
transfectants, especially prominent in core 1 and 6
(Fig. 1A). In the doxycycline-regulated cell lines,
the expression of the HCV core protein was tightly
Fig. 1. Expressions of HCV core protein in the stable transfec-
tants (cores 1, 5, and 6) and the doxycycline-regulated cell lines
(pUHD core). Detection of the HCV core protein in core 1,
core 5, and core 6 cells by Western blot analysis (A). The ex-
pression levels of the HCV core protein were di¡erent in each
clone: core 5 = +, core 1 = +++, and core 6 = ++++. Regulation
of steady-state HCV core protein expression by doxycycline in
the culture medium (B). pUHD core cells were cultured for 48
h in a medium containing the indicated concentrations of doxy-
cycline. Equal amounts of cell lysates (100 Wg) were resolved by
12% SDS^PAGE and subjected to Western blotting using anti-
core positive patient’s sera and horseradish peroxidase-conju-
gated anti-human immunoglobulin G as the primary and sec-
ondary antibodies, respectively.
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regulated over a broad range by the concentration of
doxycycline (Fig. 1B).
3.2. E¡ect of HCV core protein on the levels of pRb
and E2F-1
To investigate the e¡ect of the HCV core protein
on pRb and E2F-1 levels, we used anti-Rb or anti-
E2F-1 immunoblotting of the whole cell lysates in
both HCV core stable transfectants and doxycy-
cline-regulated cells, respectively. As shown in Fig.
2, in each case the HCV core-expressing cells, espe-
cially cores 1 and 6, showed a dramatic decrease in
the levels of pRb compared to the mock cells, where-
as E2F-1 were up-regulated in the HCV core stable
transfectants. We hypothesized that the HCV core
protein down-regulates the levels of the pRb. To
con¢rm this hypothesis, we performed anti-Rb im-
munoblotting in the doxycycline-regulated cells
(Fig. 3). When the cells were cultured for 72 h in a
medium containing various concentrations of doxy-
cycline, the pRb levels remarkably decreased (Fig.
3A), and a time-dependent decrease in the pRb levels
was seen following the HCV core protein expression
(Fig. 3B). This directly supports the role of the HCV
core protein in inducing a decrease in the pRb levels.
Consistent with stable transfectants, in doxycycline-
regulated cell lines, E2F-1 was also increased in a
concentration- and time-dependent manner (Fig.
3A,B).
3.3. E¡ect of the HCV core protein on Rb mRNA
levels
A marked decrease in the levels of pRb suggests
Fig. 3. E¡ect of HCV core protein on the levels of pRb and
E2F-1 in doxycycline-regulated cell lines. The cells were cul-
tured in the absence and presence of various doxycycline con-
centrations for 72 h (A) and cultured in the presence of doxycy-
cline (1 Wg/ml) for the indicated times (B). Consistent with the
HCV core stable transfectants, a marked decrease in the pRb
level was shown in the doxycycline-regulated cell line. Equal
amounts of cell lysates (100 Wg) were resolved by 6.5% SDS^
PAGE and subjected to Western blotting with anti-Rb or anti-
E2F-1 antibodies. Actin was used as a loading control. The
same results were shown repeatedly by three independent ex-
periments.
Fig. 2. E¡ect of HCV core protein on the levels of pRb and
E2F-1 in HCV core stable transfectants (cores 1, 5 and 6).
Note the dramatic decrease in the pRb levels in the HCV core
stable transfectants, especially in cores 1 and 6. Equal amounts
of cell lysates (100 Wg) were resolved by 6.5% SDS^PAGE and
subjected to Western blotting with monoclonal anti-Rb or anti-
E2F-1 antibodies. Actin was used as a loading control. The
same results were shown repeatedly by three independent ex-
periments.
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the possibility that the HCV core protein also de-
creases the Rb mRNA expression. To determine
whether the HCV core protein down-regulates the
Rb mRNA expression, we investigated the levels of
Rb mRNA in both HCV core stable transfectants
and doxycycline-regulated cells. As shown in Fig.
4A, the Rb mRNA levels showed a dramatic de-
crease in the core 6 cells. Consistent with the stable
transfectants, a time- and concentration-dependent
decrease in the levels of Rb mRNA was also ob-
served following the HCV core protein expression
(Fig. 4B,C).
3.4. E¡ect of HCV core protein on pRb-half life
The levels of pRb were also determined by destruc-
tion of the protein itself, by various mechanisms. Ac-
cording to pulse-chase analysis (Fig. 5), the pRb
showed a similar half-life in the mock and core 6
cells. Furthermore, consistent with previous data,
mock cells showed a slight increase in basal pRb
levels compared to core 6 cells.
3.5. E¡ect of pRb down-regulation on cell viability
To determine whether pRb down-regulation can
modulate susceptibility to cell death following con-
tact inhibition, cells were continuously cultured
5 days after 100% con£uency status.
According to the viable cell count, core 6 cells had
a ¢ve times higher cell death rate than mock cells
(Fig. 6A). Consistent with viable cell count, we also
observed that core 6 cells showed marked cell detach-
ment in overcon£uent conditions, but not in mock
cells (Fig. 6B). Fig. 6C showed that cell death was
mediated by an apoptotic process through caspase-3
activation. In addition to contact inhibition, we also
observed that core 6 cells showed increased apoptotic
cell death to various cellular stresses, such as, etopo-
side and serum starvation (data not shown). These
Fig. 4. E¡ect of HCV core protein on the levels of Rb mRNA in the HCV core stable transfectant (core 6) and doxycycline-regulated
cell lines. Note a marked decrease in the Rb mRNA levels of the core 6 cells (A). The cells were cultured in the absence and presence
of various doxycycline concentrations for 3 days (B), and cultured in the presence of doxycycline (1 Wg/ml) for the indicated times
(C). The Rb mRNA levels were dramatically decreased after HCV core protein expression. The expressions of HCV core protein were
con¢rmed by anti-core immunoblotting. The same results were shown repeatedly by three independent experiments.
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results suggest that the pRb down-regulation may
sensitize core 6 cells to apoptosis.
4. Discussion
Cancer is a multi-step process that requires an ac-
cumulative e¡ect altering the key biological path-
ways, such as the restriction point control, genome
integrity control, and cell survival or death pathway
[11,12]. The pRb, as a tumor suppressor protein,
plays a key role in a late G1 phase checkpoint con-
trol [13]. A loss of pRb function by di¡erent mech-
anisms has been reported in many human cancers
[12^14]. In addition to the loss of pRb function, re-
cent studies suggest that levels of the pRb are impor-
tant for determining of cellular fates [21,22]. DNA
tumor viruses such as adenovirus, human papilloma
virus (HPV), and SV40 virus can induce malignant
transformation by loss of pRb function [23]. In the
case of HCV, RNA virus, the correlation between
loss of pRb function and HCV core protein remains
to be elucidated.
In this study, the HCV core protein decreased the
level of pRb by down-regulation the Rb mRNA.
Kim et al. [4] also reported that the HCV core pro-
tein suppressed the expression of Rb promoters in
HepG2 cells using CAT (chloramphenicol acetyl
transferase) assay. Thus, the regulation of the Rb
expression by the HCV core protein may be modu-
lated at the transcriptional levels. However, it seems
like that level of Rb mRNA does not immediately
decrease in the presence of HCV core protein. In
addition, pRb levels were decreased 48 h after induc-
tion of HCV core protein. These results suggest that
the down-modulation of the pRb levels could be de-
layed and indirect e¡ect of the core protein overex-
pression. Furthermore, according to pulse-chase
analysis, HCV core protein cannot induce a rapid
pRb destruction observing in the presence of HPV
E7 oncoprotein.
The expression levels of E2F-1 were higher in the
HCV core stable transfectants. Unexpectedly, core 6
cells showed relatively lower E2F-1 levels than core 5
and core 1 cells, suggesting that core 6 cells with
higher E2F-1 levels may undergo apoptosis, due to
various reasons, such as, the core itself toxicity or
cell cycle perturbation during routine culture. In
fact, we usually observed that a number of core 6
cells were detached from the culture dish, whereas,
core 1 and 5 cells were not. The delicate balance
between pRb and E2F-1 is very important for deter-
mining the alternative cellular fates, such as cell pro-
liferation or apoptosis [22,24]. Overexpression of
E2F-1 can induce aberrant S-phase entry or apopto-
sis depending on cell status. The HCV core stable
transfectants used in this study grew rapidly com-
pared to the mock cells (data not shown). However,
cellular stress such as contact inhibition induced
more sensitive cell death in core 6 cells through ap-
optosis. Even though HCV core protein appears to
be capable of both inducing and blocking apoptosis
under di¡erent conditions [7,8], in this study, it was
observed that core 6 cells showed increased apoptotic
cell death to various cellular stresses, such as contact
inhibition.
Thus, our data suggest that HCV core protein can
Fig. 5. Determination of the pRb half-life. Pulse-chase analysis
of the pRb was performed in mock and core 6 cells. The cells
were metabolically pulse-labeled with [35S]methionine for 15
min and chased for various time periods. Equal amounts of cell
lysates (200 Wg) were immunoprecipitated using an anti-Rb anti-
body, and separated by 6.5% SDS^PAGE. pRb signals de-
creased with similar kinetics in mock and core 6 cells. Quanti¢-
cation of pRb signals was performed with a densitometer
(Scion Corp.).
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Fig. 6. E¡ect of HCV core protein on the viabilities of mock and core 6 cells in overcon£uent growth. Cells were continuously cul-
tured 5 days after 100% con£uency status. Trypan blue exclusion assay (A), cell morphologies (B), and caspase-3 activity showed that
core 6 cells were more sensitive to cell death following contact inhibition than mock cells. Photographs were taken after crystal violet
staining using an inverted phase contrast microscope (U100). Enzymatic ac-DEVD-pNA cleavage activity was monitored on a spectro-
photometer (Amersham Pharmacia) at an absorbance of 405 nm (C).
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induce a down-regulation of pRb levels by a delayed
or indirect pathway, and the release of active E2F
transcription factors and accumulation of E2F-1 may
result on deregulating the Rb pathway by other
means. Consequently, disruption of pRb/E2F-1 bal-
ance by the HCV core protein may result in in-
creased cell proliferation or making cells prone to
apoptosis, depending on the conditions. However,
to progress into hepatocellular cell carcinoma, virus
infected cells should overcome the apoptotic path-
way. To understand hepatocarcinogenesis by HCV
infection, it is necessary to investigate how HCV
core protein can inhibit the apoptotic process in
the presence of Rb pathway perturbation.
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